Neutrophil Cathepsin G, but Not Elastase, Induces Aggregation of MCF-7 Mammary Carcinoma Cells by a Protease Activity-Dependent Cell-Oriented Mechanism

Mediators of Inflammation - Tập 2014 - Trang 1-12 - 2014
Satoru Yui1, Yuuki Osawa1, Takeo Ichisugi1, Riyo Morimoto‐Kamata1
1Laboratory of Host Defense, Department of Pharma-Sciences, Teikyo University, 2-11-1 Kaga, Itabashi-ku, Tokyo 173-8605, Japan

Tóm tắt

We previously found that a neutrophil serine protease, cathepsin G, weakens adherence to culture substrates and induces E-cadherin-dependent aggregation of MCF-7 human breast cancer cells through its protease activity. In this study, we examined whether aggregation is caused by degradation of adhesion molecules on the culture substrates or through an unidentified mechanism. We compared the effect of treatment with cathepsin G and other proteases, including neutrophil elastase against fibronectin- (FN-) coated substrates. Cathepsin G and elastase potently degraded FN on the substrates and induced aggregation of MCF-7 cells that had been subsequently seeded onto the substrate. However, substrate-bound cathepsin G and elastase may have caused cell aggregation. After inhibiting the proteases on the culture substrates using the irreversible inhibitor phenylmethylsulfonyl fluoride (PMSF), we examined whether aggregation of MCF-7 cells was suppressed. PMSF attenuated cell aggregation on cathepsin G-treated substrates, but the effect was weak in cells pretreated with high concentrations of cathepsin G. In contrast, PMSF did not suppress cell aggregation on elastase-treated FN. Moreover, cathepsin G, but not elastase, induced aggregation on poly-L-lysine substrates which are not decomposed by these enzymes, and the action of cathepsin G was nearly completely attenuated by PMSF. These results suggest that cathepsin G induces MCF-7 aggregation through a cell-oriented mechanism.

Từ khóa


Tài liệu tham khảo

2013, Journal of Cell Science, 126, 393, 10.1242/jcs.100115

1997, Cancer, 80, 1529

1997, British Journal of Cancer, 75, 623, 10.1038/bjc.1997.113

1988, Biochimica et Biophysica Acta, 948, 175

10.1016/S0304-419X(01)00038-5

1973, European Journal of Cancer, 9, 223, 10.1016/S0014-2964(73)80022-2

1976, Cancer Research, 36, 889

2001, Cancer Research, 61, 5231

1976, International Journal of Cancer, 18, 331, 10.1002/ijc.2910180310

10.1016/S0140-6736(00)04046-0

10.1023/A:1015587423262

10.1182/blood.V97.2.339

10.1016/j.critrevonc.2011.06.004

10.1111/j.1349-7006.2005.00097.x

10.1155/2009/850940

1999, Journal of Leukocyte Biology, 65, 137, 10.1002/jlb.65.2.137

10.1038/nri1841

10.1128/IAI.68.10.5668-5672.2000

1996, Infection and Immunity, 64, 4842, 10.1128/IAI.64.11.4842-4845.1996

10.1128/IAI.05593-11

1990, Biochemical Journal, 266, 55, 10.1042/bj2660055

10.1074/jbc.275.10.6819

2004, The Journal of Immunology, 173, 428, 10.4049/jimmunol.173.1.428

2003, The Journal of Immunology, 170, 5690, 10.4049/jimmunol.170.11.5690

2001, British Journal of Pharmacology, 133, 422, 10.1038/sj.bjp.0704089

10.1074/jbc.M302718200

10.1161/01.ATV.15.11.2037

10.1155/2012/456462

2005, Journal of Internal Medicine, 257, 319, 10.1111/j.1365-2796.2005.01476.x

1980, The Journal of Biological Chemistry, 255, 8848, 10.1016/S0021-9258(18)43580-6

1981, The Journal of Biological Chemistry, 256, 471, 10.1016/S0021-9258(19)70161-6

10.1016/S0049-3848(99)00242-X

1989, Journal of Cell Science, 93, 641, 10.1242/jcs.93.4.641

1988, Development, 102, 639, 10.1242/dev.102.4.639

1979, The Journal of Biological Chemistry, 254, 4027, 10.1016/S0021-9258(18)50690-6

1995, Seminars in Cell Biology, 6, 367, 10.1016/S1043-4682(05)80007-8

10.1182/blood-2010-05-287722

10.1016/j.immuni.2005.03.015